Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

INDUSTRY 5OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 18Neoplasms 10Adenocarcinoma 8Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 6Esophageal Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Colonic Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Melanoma 3Liver Neoplasms 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Solid Tumor 1Solid Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1

Interventions

pembrolizumab 40Cisplatin 25Fluorouracil 24Paclitaxel 21Oxaliplatin 16Capecitabine 12Leucovorin 10Irinotecan 10Docetaxel 10Gemcitabine 8Carboplatin 7atezolizumab 6Nivolumab 6Bevacizumab 6Trastuzumab 5Ramucirumab 5Radiotherapy 5spartalizumab 4Albumin-Bound Paclitaxel 4zanidatamab 3tisotumab vedotin 3patritumab deruxtecan 3lenvatinib 3fludarabine 3durvalumab 3Radiation 3Drug Therapy 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Neoplasms × Ramucirumab × Clear all
NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
214 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT02970539 2022-02-16

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Athenex, Inc.

Phase 1 Unknown
36 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01246960 2014-10-08

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Eli Lilly and Company

Phase 2 Completed
168 enrolled 16 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡